IOM urges FDA to be more aggressive in monitoring safety of approved drugs.
Bridget M
BM
Kuehn
D003920:Diabetes Mellitus / Q000188:drug therapy; D017277:Drug Approval; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects; D015969:National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division; D061214:Patient Safety; D011358:Product Surveillance, Postmarketing; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone